These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

67 related items for PubMed ID: 24974054

  • 1. Tissue factor pathway inhibitor and thrombin-activatable carboxypeptidase B for prediction of early atherosclerosis in gouty arthritis.
    Uyanik MS, Pamuk GE, Pamuk ON, Tuncel SA.
    Thromb Res; 2014 Aug; 134(2):526-30. PubMed ID: 24974054
    [Abstract] [Full Text] [Related]

  • 2. Subclinical atherosclerosis in gouty arthritis patients: a comparative study.
    Çukurova S, Pamuk ÖN, Ünlü E, Pamuk GE, Çakir N.
    Rheumatol Int; 2012 Jun; 32(6):1769-73. PubMed ID: 21442166
    [Abstract] [Full Text] [Related]

  • 3. Plasma thrombin-activatable fibrinolysis inhibitor levels are not associated with glucose intolerance and subclinical atherosclerosis in women with previous gestational diabetes.
    Akinci B, Celtik A, Yener S, Genc S, Tunali S, Yuksel F, Ozcan MA, Secil M, Yesil S.
    Clin Appl Thromb Hemost; 2011 Jun; 17(6):E224-30. PubMed ID: 21406417
    [Abstract] [Full Text] [Related]

  • 4. TFPI antigen and activity levels in patients with asymptomatic atherosclerosis and target organ acute and chronic complications.
    Novo G, Caplice N, Tantillo R, Bonura F, Simari R, Novo S.
    Int Angiol; 2005 Dec; 24(4):366-71. PubMed ID: 16355095
    [Abstract] [Full Text] [Related]

  • 5. Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism.
    Erem C, Kocak M, Nuhoglu I, Yilmaz M, Ucuncu O.
    Eur J Endocrinol; 2009 May; 160(5):863-8. PubMed ID: 19233920
    [Abstract] [Full Text] [Related]

  • 6. Blood coagulation and fibrinolysis in patients with acromegaly: increased plasminogen activator inhibitor-1 (PAI-1), decreased tissue factor pathway inhibitor (TFPI), and an inverse correlation between growth hormone and TFPI.
    Erem C, Nuhoglu I, Kocak M, Yilmaz M, Sipahi ST, Ucuncu O, Ersoz HO.
    Endocrine; 2008 Jun; 33(3):270-6. PubMed ID: 19016004
    [Abstract] [Full Text] [Related]

  • 7. Circulating monocytes mirror the imbalance in TF and TFPI expression in carotid atherosclerotic plaques with lipid-rich and calcified morphology.
    Basavaraj MG, Sovershaev MA, Egorina EM, Gruber FX, Bogdanov VY, Fallon JT, Østerud B, Mathiesen EB, Hansen JB.
    Thromb Res; 2012 Apr; 129(4):e134-41. PubMed ID: 22178066
    [Abstract] [Full Text] [Related]

  • 8. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hypothyroidism.
    Erem C, Ucuncu O, Yilmaz M, Kocak M, Nuhoglu I, Ersoz HO.
    Endocrine; 2009 Feb; 35(1):75-80. PubMed ID: 18958631
    [Abstract] [Full Text] [Related]

  • 9. Tissue factor, tissue pathway factor inhibitor and risk factors of atherosclerosis in patients with chronic limbs ischemia: preliminary study.
    Gosk-Bierska I, Wysokin Ski W, Karnicki K, Adamiec R.
    Int Angiol; 2008 Aug; 27(4):296-301. PubMed ID: 18677291
    [Abstract] [Full Text] [Related]

  • 10. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hyperthyroidism.
    Erem C, Ucuncu O, Yilmaz M, Kocak M, Nuhoglu İ, Ersoz HO.
    Endocrine; 2009 Dec; 36(3):473-8. PubMed ID: 19859836
    [Abstract] [Full Text] [Related]

  • 11. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor and thrombomodulin levels in children with hypothyroidism.
    Alioğlu B, Kılıç N, Şimşek E, Dallar Y.
    J Clin Res Pediatr Endocrinol; 2012 Sep; 4(3):146-50. PubMed ID: 22985614
    [Abstract] [Full Text] [Related]

  • 12. Postprandial thrombin activatable fibrinolysis inhibitor and markers of endothelial dysfunction in type 2 diabetic patients.
    Rigla M, Wägner AM, Borrell M, Mateo J, Foncuberta J, de Leiva A, Ordóñez-Llanos J, Pérez A.
    Metabolism; 2006 Nov; 55(11):1437-42. PubMed ID: 17046544
    [Abstract] [Full Text] [Related]

  • 13. Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism.
    Ermantas N, Guldiken S, Demir M, Tugrul A.
    Clin Appl Thromb Hemost; 2010 Oct; 16(5):568-73. PubMed ID: 19959491
    [Abstract] [Full Text] [Related]

  • 14. Effect of long-term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study.
    Bladbjerg EM, Madsen JS, Kristensen SR, Abrahamsen B, Brixen K, Mosekilde L, Jespersen J.
    J Thromb Haemost; 2003 Jun; 1(6):1208-14. PubMed ID: 12871321
    [Abstract] [Full Text] [Related]

  • 15. Thrombin activatable fibrinolysis inhibitor (TAFI) and markers of endothelial cell injury in dialyzed patients with diabetic nephropathy.
    Małyszko J, Małyszko JS, Hryszko T, Myśliwiec M.
    Thromb Haemost; 2004 Mar; 91(3):480-6. PubMed ID: 14983223
    [Abstract] [Full Text] [Related]

  • 16. Levels of TAFI, TFPI and ADAMTS-13 in inflammatory bowel disease.
    Yüzbaşıoğlu B, Ustaoğlu M, Yüzbaşıoğlu Ş, Akbulut UE, Özdil K.
    Turk J Gastroenterol; 2019 Dec; 30(12):1025-1029. PubMed ID: 31854307
    [Abstract] [Full Text] [Related]

  • 17. Plasma thrombin-activatable fibrinolysis inhibitor levels and its Thr325Ile polymorphism in breast cancer.
    Chengwei X, Xiaoli M, Yuan Z, Li P, Shengjiang W, Chao Y, Yunshan W.
    Blood Coagul Fibrinolysis; 2013 Oct; 24(7):698-703. PubMed ID: 23624357
    [Abstract] [Full Text] [Related]

  • 18. Blood coagulation, fibrinolysis and lipid profile in patients with prolactinoma.
    Erem C, Kocak M, Nuhoglu I, Yılmaz M, Ucuncu O.
    Clin Endocrinol (Oxf); 2010 Oct; 73(4):502-7. PubMed ID: 20039901
    [Abstract] [Full Text] [Related]

  • 19. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients.
    Falciani M, Gori AM, Fedi S, Chiarugi L, Simonetti I, Dabizzi RP, Prisco D, Pepe G, Abbate R, Gensini GF, Neri Serneri GG.
    Thromb Haemost; 1998 Mar; 79(3):495-9. PubMed ID: 9531029
    [Abstract] [Full Text] [Related]

  • 20. Tissue factor, tissue factor pathway inhibitor and vascular endothelial growth factor-A in carotid atherosclerotic plaques.
    Migdalski A, Kotschy M, Jawien A.
    Eur J Vasc Endovasc Surg; 2005 Jul; 30(1):41-7. PubMed ID: 15933981
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.